- Home
- HIG vs HURA Comparison
HIG vs HURA Comparison
Compare HIG & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | HIG | HURA |
|---|---|---|
| Founded | 1810 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.3B | 35.5M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | HIG | HURA |
|---|---|---|
| Price | $141.07 | $1.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 1 |
| Target Price | ★ $149.25 | $10.00 |
| AVG Volume (30 Days) | 1.6M | ★ 3.3M |
| Earning Date | 01-29-2026 | 03-31-2026 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | ★ 28.70 | N/A |
| EPS | ★ 13.32 | N/A |
| Revenue | ★ $28,368,000,000.00 | N/A |
| Revenue This Year | $6.24 | N/A |
| Revenue Next Year | $4.29 | N/A |
| P/E Ratio | $10.65 | ★ N/A |
| Revenue Growth | ★ 6.81 | N/A |
| 52 Week Low | $107.49 | $0.41 |
| 52 Week High | $144.50 | $4.77 |
Technical Indicators
Market Signals| Indicator | HIG | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 61.50 | 73.78 |
| Support Level | $138.93 | $0.42 |
| Resistance Level | $143.80 | $1.51 |
| Average True Range (ATR) | 2.64 | 0.18 |
| MACD | 0.75 | 0.12 |
| Stochastic Oscillator | 80.10 | 84.55 |
Price Performance
Historical ComparisonAbout HIG Hartford Financial Services Group Inc. (The)
The Hartford Insurance Group Inc. provides property and casualty insurance, group benefits, and mutual funds. The company is widely recognized for its service excellence, sustainability practices, trust, and integrity. The Company currently conducts business principally in five reportable segments including Business Insurance, Personal Insurance, Property & Casualty Other Operations, Employee Benefits, and Hartford Funds, as well as a Corporate category. The company generates a majority of its revenue from Business Insurance.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.